USPTO to review Alkermes Vivitrol patent

|About: Alkermes plc (ALKS)|By:, SA News Editor

Alkermes plc (NASDAQ:ALKS) discloses that the USPTO's Patent Trial and Appeal Board will allow an inter partes review of 13 claims of its U.S. Patent No. 7,919,499 protecting top seller VIVITROL (naltrexone for extended-release injectable suspension) following its review of a petition filed by would-be generic competitor Amneal Pharmaceuticals, LLC.

A decision is expected by November 7, 2019.

Subscribe for full text news in your inbox